Raymond James & Associates’s Intersect ENT, Inc XENT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q2 | – | Sell |
-42,713
| Closed | -$1.2M | – | 4301 |
|
|
2022
Q1 | $1.2M | Buy |
42,713
+2,717
| +7% | +$74.5K | ﹤0.01% | 2475 |
|
|
2021
Q4 | $1.09M | Buy |
39,996
+4,045
| +11% | +$110K | ﹤0.01% | 2566 |
|
|
2021
Q3 | $978K | Buy |
+35,951
| New | +$889K | ﹤0.01% | 2601 |
|
|
2018
Q3 | – | Sell |
-10,208
| Closed | -$382K | – | 3757 |
|
|
2018
Q2 | $382K | Buy |
10,208
+1,756
| +21% | +$68.9K | ﹤0.01% | 2860 |
|
|
2018
Q1 | $332K | Sell |
8,452
-81,822
| -91% | -$2.99M | ﹤0.01% | 2828 |
|
|
2017
Q4 | $2.92M | Sell |
90,274
-2,747
| -3% | -$82.4K | 0.01% | 1440 |
|
|
2017
Q3 | $2.9M | Buy |
93,021
+5,264
| +6% | +$156K | 0.01% | 1383 |
|
|
2017
Q2 | $2.45M | Buy |
87,757
+1,744
| +2% | +$39.5K | 0.01% | 1433 |
|
|
2017
Q1 | $1.48M | Buy |
86,013
+7,838
| +10% | +$110K | ﹤0.01% | 1730 |
|
|
2016
Q4 | $946K | Sell |
78,175
-9,918
| -11% | -$128K | ﹤0.01% | 1950 |
|
|
2016
Q3 | $1.4M | Sell |
88,093
-32
| -0% | -$482 | ﹤0.01% | 1672 |
|
|
2016
Q2 | $1.14M | Buy |
88,125
+7,013
| +9% | +$110K | ﹤0.01% | 1665 |
|
|
2016
Q1 | $1.54M | Buy |
81,112
+19,153
| +31% | +$347K | 0.01% | 1438 |
|
|
2015
Q4 | $1.39M | Buy |
61,959
+34
| +0.1% | +$672 | 0.01% | 1455 |
|
|
2015
Q3 | $1.45M | Buy |
+61,925
| New | +$1.71M | 0.01% | 1397 |
|
Raymond James & Associates's XENT Position: Q2 2022 in Review
Raymond James & Associates sold out of Intersect ENT, Inc (XENT) in Q2 2022, closing a stake of 42,713 shares — an estimated $1.2M sold.
Raymond James & Associates first reported a position in XENT in Q3 2015 and held it in 15 quarters. The position peaked at $2.92M in Q4 2017. 0 funds tracked by Wall St. Rank hold XENT as of Q2 2022.
- Raymond James & Associates reported no remaining Intersect ENT, Inc position as of Q2 2022 after selling out during the quarter.
- Raymond James & Associates sold 42,713 Intersect ENT, Inc shares in Q2 2022, an estimated $1.2M.
- Raymond James & Associates first reported a position in Intersect ENT, Inc in Q3 2015 and held it in 15 quarters.
- Raymond James & Associates's Intersect ENT, Inc position peaked at $2.92M in Q4 2017.
- 0 funds tracked by Wall St. Rank held Intersect ENT, Inc as of Q2 2022.
Based on Raymond James & Associates's 13F filing for Q2 2022, filed 12 Aug 2022.